Avantia Labs

Avantia Labs is a specialized bioanalytical CRO founded in 2019, offering a critical suite of services for the development of complex biologics and cell and gene therapies (CGT). Its key differentiator is the provision of the MAPPs immunogenicity risk assessment assay, a sophisticated ex vivo platform that identifies peptide–MHC complexes to predict immunogenic epitopes early in drug development. The company supports clients with end-to-end solutions in pharmacokinetics, immunogenicity, biomarker profiling, and CGT analytics using advanced platforms like ddPCR, qPCR, MSD, and cell-based assays. By focusing on regulatory compliance and scientific partnership, Avantia aims to reduce development risk and accelerate time-to-clinic for novel therapeutics.

Integrated bioanalytical platform specializing in large molecule and cell/gene therapy analysis. Core technologies include MHC-II Associated Peptide Proteomics (MAPPs) for immunogenicity risk assessment, digital droplet PCR (ddPCR) and qPCR for vector/genome quantification, MSD/ELISA for PK/ADA assays, and a suite of cell-based functional and potency assays (e.g., ELISpot, flow cytometry).

Avantia competes in the bioanalytical CRO segment against large players like Labcorp, IQVIA, and Charles River Laboratories, which offer broad services but may lack deep specialization. It also faces competition from other focused CROs such as BioAgilytix (strong in immunogenicity and biomarkers), Q2 Solutions, and smaller niche labs. Its primary competitive advantage is the combination of the MAPPs assay with deep expertise in cell/gene therapy analytics under one roof.